China’s Innovative Drug Exports Surge to $110B in H1 2026
Chinese pharmaceutical companies are accelerating their global expansion at an unprecedented pace, with innovative drug out-licensing deals reaching approximately $110 billion across 81 transactions in the first half of 2026, according to Xinhua News. The figure exceeds 80 percent of the full-year 2025 total and more than doubles the 2024 level, signaling a fundamental transformation in China’s pharmaceutical sector—from a producer of inexpensive generics to a source of first-in-class innovations that global pharmaceutical giants are actively seeking to license.
The deals span 10 major therapeutic areas including oncology, metabolism, immunology, and neurology, with partners from more than 20 countries and regions including the United States, France, the United Kingdom, and Italy. Industry analysts expect 2026 to set a new record for Chinese biotech out-licensing transactions.
A Landmark Year for Licensing Deals
The surge has been driven by several landmark transactions. In January, UK pharmaceutical giant AstraZeneca signed a deal worth up to $18.5 billion with Chinese drugmaker CSPC Pharmaceutical Group for eight long-acting peptide drug programs targeting weight loss and Type 2 diabetes. As Chemical & Engineering News reported, the agreement includes a $1.2 billion upfront payment, up to $3.5 billion in development and regulatory milestones, and potential sales milestones of $13.8 billion—making it one of the largest weight-loss-drug collaborations ever and outpacing GSK’s $12.5 billion agreement with Jiangsu Hengrui Pharmaceuticals from July 2025.
In May, Innovent Biologics and Pfizer announced a global strategic licensing and collaboration agreement worth up to $10.5 billion covering 12 oncology early-stage and source innovation projects. According to Lanjinger, the deal includes a $650 million upfront payment and up to $9.85 billion in potential milestones, with Innovent retaining Greater China rights for co-developed projects and participating in profit-sharing in the US and Europe.
March saw Sino Biopharmaceutical sign a $1.53 billion exclusive licensing agreement with Sanofi for Rovatatinib, the world’s first JAK/ROCK dual-target small molecule inhibitor approved in China for myelofibrosis and graft-versus-host disease. As 21st Century Business Herald noted, this represented the largest deal by a Chinese pharmaceutical company in the transplantation field and was notable for involving a mature, commercialized asset rather than an early-stage pipeline candidate.
More recently, in July, Sino Biopharmaceutical licensed the overseas rights of its COPD drug TQC3721 to AstraZeneca for up to $1.9 billion—the largest single-product out-licensing deal in China’s respiratory field in nearly three years, as reported by Sina Finance.
From Product Export to Capability Export
Chinese pharmaceutical companies are fundamentally changing how they participate in global innovation. Rather than simply selling products and waiting for royalties, they are now operating as equal partners in joint development and profit-sharing arrangements.
“Licensing cooperation allows Chinese pharma companies to quickly recoup funds and reinvest in R&D,” Li Xin, executive director of Junshi Biosciences, told Xinhua. “Chinese companies leverage multinational corporations’ mature overseas systems for global product launch and accumulate globalization experience.”
Zhou Hui, chief R&D officer of Innovent’s oncology pipeline, emphasized the shift in power dynamics: “The core value of this agreement is ‘equality.’ Chinese pharma companies have accelerated from ‘followers’ to ‘co-builders’ in global innovation.”
The Wall Street Journal has noted that global big pharma is turning to China for innovation inspiration, with China becoming a major player in biotechnology. The cooperation model has evolved from simple product licensing to technology platform output, co-development and co-commercialization (Co-Co), and NewCo models. In 2025, over half of Chinese innovative drugs licensed out were at the pre-clinical or Phase I stage, reflecting growing confidence in early-stage Chinese innovation.
Industry Transformation and Policy Support
The acceleration in out-licensing reflects deeper structural changes in China’s pharmaceutical industry. According to CCTV News, 38 innovative drugs were approved in China in H1 2026, with 31 (over 80 percent) being domestically developed. All 11 new target/mechanism drugs were domestically developed, and by the end of 2025, China had 4,751 innovative drugs in R&D—one-third of the global total, making it the world’s largest country for drugs in research and development.
Policy support has been instrumental. The China Drug Price Registration System, launched in 2025, provides multilingual price certificates that support international market expansion. The National Health 15th Five-Year Plan and other innovative drug policies implemented in 2026 continue to encourage R&D investment. Drug review and approval reforms have accelerated time-to-market, while medical insurance negotiations have stabilized market expectations.
Xu Haoyu, president of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber, told Banyuetan that “top-level design efforts continue to strengthen, policy dividends continue to be released, and industry confidence and momentum continue to grow.”
Cost advantages also play a critical role. Cell culture media—a key biopharmaceutical raw material previously monopolized by foreign companies at RMB 400-600 per liter—now costs just RMB 20+ per liter from domestic suppliers. French newspaper Libération has reported that Chinese innovative drugs are priced significantly lower than comparable European and US products, with some cancer treatments entering the French healthcare system potentially saving patients tens of thousands of euros per year.
Global Implications
The surge in Chinese innovative drug exports comes at a critical moment for the global pharmaceutical industry. Major pharmaceutical companies face a “patent cliff” as many blockbuster products’ patents expire, creating urgent demand for innovative pipelines. Reuters has noted that licensing Chinese biotech patents costs far less than self-development, while the New York Times has observed that expanding Chinese innovative drug supply enriches global treatment options and helps lower drug prices.
Global pharmaceutical giants are investing heavily in China to participate in this innovation ecosystem. AstraZeneca has committed $15 billion to expand manufacturing and R&D in China through 2030, including a cell therapy innovation center in Shanghai’s Zhangjiang district. Novartis has announced over RMB 3.3 billion in new investment for its Beijing Changping production base expansion.
As Global Times editorialized, China’s innovative medicines represent part of the country’s “next new three”—alongside AI and robotics—that are bringing “accessible intelligence” to the world. The publication noted that the disclosed potential total value of out-licensing deals for Chinese innovative drugs reached approximately $110 billion, with Chinese companies and multinational pharmaceutical firms forging R&D partnerships characterized by deep mutual integration.
What to Watch For
Industry observers expect 2026 to set a new record for Chinese biotech out-licensing transactions. Key indicators to monitor include the pace of new deals in the second half of the year, the progression of early-stage assets through clinical development, and whether the co-development models pioneered this year become the industry standard.
Questions also remain about how the trend will affect drug pricing and access globally. While the expansion of Chinese innovative drug supply is widely seen as beneficial for patients worldwide, the long-term implications for global pharmaceutical competition and pricing dynamics are still unfolding. What is clear is that China’s pharmaceutical industry has entered a new era—one in which its innovations are increasingly shaping the global healthcare landscape.